Strategic Acquisition SIGMA became part of the ZETA Group in 2022 and was fully acquired by ZETA Biopharma in October 2025, signaling strong integration with a global pharma/biotech EPCM contractor. Sales teams should position combined capabilities to access larger pharma and biotech project opportunities, especially in process automation and manufacturing intelligence.

Industry Focus Deep specialization in process automation for pharma, biotech, vaccine development, diagnostics, and chemical sectors, with additional exposure to food & beverage and water treatment. Leverage this domain depth to tailor solutions around compliance, traceability, and enhanced process efficiency for target customers in regulated industries.

Growth Readiness Revenue in the mid single digits to low tens of millions and a lean team (51-200 employees) suggest agility and potential for scalable automation projects. Target mid-market to upper-mid-market pharma/biotech clients looking for specialized systems integration, custom automation, and manufacturing intelligence without lengthy procurement.

Technology Stack Core tools include DATEV, Tableau, Microsoft 365, Linux, C++, C#, VMware, and other enterprise platforms, indicating capabilities for data analytics, ERP integration, and robust IT/OT alignment. Upsell opportunities exist in data visualization, performance analytics, and secure, scalable automation architectures.

Partnership Synergy Strategic alignment with ZETA Group creates a compelling value proposition for customers seeking end-to-end automation from a trusted, integrated provider. Use this to differentiate from competitors and pursue joint bids for pharma/biotech manufacturing facilities, with emphasis on compliance, GMP readiness, and project delivery certainty.